Latest Share Chat

CLIN.L Share News (CLIN)

CLIN.L Information

There is currently no data for CLIN

Clinigen bounds upwards on purchase of Proleukin's US rights

Wed, 13th Feb 2019 10:05

(Sharecast News) - Clinigen Group shares jumped on Wednesday after the company signed an agreement with Novartis to acquire the US rights to its Proleukin drug for up to $210m in cash.Clinigen, which already acquired the rights to Proleukin outside the US in July, will pay an initial $120m, with $60m deferred over the next 12 months and then a further $30m depending on the drug's sales.In the year to 30 June 2018, metastatic melanoma and metastatic renal cell carcinoma treatment Proleukin made US-based revenue of $60.0m according to IQvia, with the drug's gross profit margin expected to be similar to other specialty medicines within Clinigen's Commercial Medicines division.As such, the acquisition is expected to be "modestly" EPS accretive in the current financial year as the product transitions to the AIM traded company, and at least 25% accretive in the first full financial year.Shaun Chilton, chief executive of Clinigen, said: "As part of Commercial Medicines, Proleukin is an excellent fit within our oncology and infectious disease medicines as well as diversifying our wider portfolio - it will be the largest product in the portfolio in terms of current sales. The product has significant potential for revitalisation, which will provide further breadth and diversity to the portfolio and material increases in revenues."The company currently owns three product assets within the US, Foscavir, Ethyol and Totect, with commercial rights for the former currently licensed to Pfizer and to Cumberland Pharmaceuticals for the other two."For Clinigen as a whole, Proleukin creates an ideal platform to expand our existing footprint in the higher value US market and therefore enables us to exploit other opportunities across the business. This follows our acquisition last year of CSM and iQone which strengthened our Continental European footprint. At the financial level, the combination of this deal structure and the group's cash generative nature will ensure our debt profile reduces quickly over the next year," said Chilton.For the six-month period ended 31 December, the company said it expects adjusted EBITDA to have expanded from £34.4m to £41.8m and also reported that it has increased its debt facility from £300m to £375m, with the terms of the extended debt remain unchanged and the facility in place until October 2023.Clinigen's shares were up 13.71% at 838.60p at 0923 GMT.

More News

18 Jun 2018 16:22

Abcam Appoints Former Celltech CFO As Non-Executive Chairman

LONDON (Alliance News) - Life sciences company Abcam PLC said Monday it has appointed the former chief financial officer of Celtech Group PLC as a non-executive chairman.Peter Allen is a at

8 May 2018 12:06

Benchmark Appoints Clinigen Founder And Former Boss As New Chairman

LONDON (Alliance News) - Benchmark Holdings PLC said Tuesday it appointed Peter George as chairman with immediate effect.George founded and was chief executive officer of FTSE-listed Group

19 Mar 2018 08:34

Clinigen To Run Vyxeos Managed Access Program For Jazz Pharmaceuticals

LONDON (Alliance News) - Pharmaceutical firm Clinigen Group PLC has been appointed by Nasdaq-listed Jazz Pharmaceuticals PLC to distribute Vyxeos via a managed access outside

25 Jan 2017 16:47

Clinigen profits rise by a third

(ShareCast News) - Global pharmaceutical and services company Clinigen Group provided a trading update for the six months to 31 December on Wednesday, with gross profit up 34%. The AIM-traded firm said this was driven by a combination of "good" organic growth across all divisions, a full six months

18 Jan 2017 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

17 Jan 2017 14:10

Clinigen division teams up with TESARO

(ShareCast News) - Clinigen Group announced on Tuesday that its Idis Managed Access division has partnered with TESARO to launch a managed access program for the investigational PARP 1/2 inhibitor, niraparib. The AIM-traded company said Niraparib is being made available for eligible women in the U.S

9 Jan 2017 15:57

Clinigen enters into second agreement with Cumberland Pharmaceuticals

(ShareCast News) - Clinigen Group, an AIM listed global pharmaceutical and services company, and Cumberland Pharmaceuticals, a US specialty pharmaceutical company have entered into their second exclusive agreement to commercialise the oncology support drug Totect in the US. The first product Clinige

9 Jan 2017 14:51

Clinigen Group Gives Exclusive US Licence For Totect To Cumberland

15 Dec 2016 09:08

Clinigen to distribute BioQ's pain relief drug in Europe

(ShareCast News) - AIM-listed pharmaceutical Clinigen is to distribute BioQ Pharma's post-surgery pain management drug, Ropivacaine Readyfusor. The company's subsidiary Idis Global Access has agreed to supply and distribute the pre-filled Ropivacaine Readyfusor for post-operative pain management in

15 Dec 2016 07:58

Clinigen's Idis Signs Distribution Deal With BioQ Pharma

1 Dec 2016 11:03

Clinigen and Eisai launch breast cancer treatment in South Africa

(ShareCast News) - Pharmaceutical companies Clinigen and Eisai launched an advanced breast cancer treatment for women in South Africa called Halaven (eribulin). The treatment will benefit around 7,000 women in South Africa that are diagnosed with breast cancer each year. Halaven is now registered b

1 Dec 2016 07:53

Clinigen's Halaven Breast Cancer Drug Registered In South Africa

14 Nov 2016 15:07

Director dealings: Clinigen's Bacon slices off a chunk

(ShareCast News) - Clinigen Group director John Bacon has sold £1.4m of the pharmaceuticals and clinical trial services group. Bacon sold 200,000 shares at a price of 717p apiece, but still holds 730,767 shares in the company. He had originally joined the board as a non-executive director last year

11 Nov 2016 13:40

Clinigen says trading in-line for current FY

(ShareCast News) - Global pharmaceutical and services company Clinigen Group said its trading for the current financial year is in-line with directors' expectations. It said the year to 30 June marked the completion of its transformation into the global market leader in the management and supply of

11 Nov 2016 07:19

Latest Share Chat

CLIN.L Share News (CLIN)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Clinigen bounds upwards on purchase of Proleukin's US rights

Login to your account

Quickpicks are a member only feature

Login to your account